HealthQuill Novatis AG
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More
Novartis AG, one of the world’s top 10 pharmaceutical companies in terms of revenue, will acquire US-based Anthos Therapeutics Inc. for $3.1 billion to expand its cardiovascular pipeline.
Uncategorized

Switzerland’s Novartis to buy US-based Anthos for $3.1 billion

Novartis AG, one of the world’s top 10 pharmaceutical companies in terms of revenue, will acquire US-based Anthos Therapeutics Inc. for $3.1 billion.

Read More